Cambridge Cognition Holdings PLC Trading Update (7590Z)
27 Enero 2022 - 12:59AM
UK Regulatory
TIDMCOG
RNS Number : 7590Z
Cambridge Cognition Holdings PLC
27 January 2022
27 January 2022
Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
Trading Update
Strong orders and revenue growth on adoption of virtual clinical
trials and broader product offering
Cambridge Cognition Holdings plc (AIM: COG), which develops and
markets digital solutions to assess brain health, is pleased to
announce a positive trading update for the year ended 31 December
2021.
Unaudited highlights for the year ended 31 December 2021
-- Growth in revenues of 50% to GBP10.1 million (2020: GBP6.7 million)
-- Increase in contracted order backlog of 51% to GBP17.0
million (31 December 2020: GBP11.2 million)
-- Profit after tax for the year of GBP0.5 million (2020: GBP0.4 million loss)
-- Cash balance of GBP6.8 million at 31 December 2021 (31 December 2020: GBP3.0 million)
The Company made excellent progress in 2021, delivering strong
growth in orders and revenues, together with moving into
profitability with earnings ahead of market expectations. Order
intake for the year closed at GBP15.7 million, up 25% on the
previous year's order intake of GBP12.7 million. Order growth
continued to be driven by commercial execution, a broader product
offering and demand for virtual clinical trials. The contracted
order book at the end of 2021 was GBP17.0 million (GBP11.2 million
at 31 December 2020) of which at least GBP7.5 million is expected
to be recognised as revenue in 2022, subject to customer delivery
schedules.
The pandemic has provided a catalyst for the growth in adoption
of virtual clinical trials as pharmaceutical companies shift to
measuring patients at home more(1) , which has been of benefit to
the Company, but this has been offset to a certain extent by some
delays to trials(2) , mostly due to more cautious, slower patient
recruitment. These trends are expected to continue in 2022.
The underlying market for the measurement of electronic outcomes
in clinical trials was reported to be growing at 17%(3) in 2021.
The Company results were ahead of this underlying market growth.
The 2021 performance provides a strong platform for further growth
as the Company continues to develop and commercialise its
innovative digital assessments, primarily for clinical trials.
The Company expects to announce its preliminary results in March
2022.
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
References.
1. McKinsey & Company. (2021). https://www.mckinsey.com/industries/life-sciences/our-insights/no-place-like-home-stepping-up-the-decentralization-of-clinical-trials
2. John Z. Xue et al., "Clinical trial recovery from COVID-19
disruption," Nature Reviews Drug Discovery, September 2020, Volume
19, pp. 662-3, nature.com. Monthly trial starts declined 50% from
January 2020 to April 2020, and 60% of investigators reported a
significant reduction in trial activities in May 2020.
3. GrandView Research 2018 eCOA Report indicates a CAGR of 17% 2018-20225
Enquiries:
Cambridge Cognition Holdings plc Tel: 01223 810 700
Matthew Stork, Chief Executive Officer press@camcog.com
Steven Powell, Chairman
finnCap Ltd (Nomad and Joint Broker) Tel: 020 7220 0500
Geoff Nash/ Simon Hicks (Corporate Finance)
Alice Lane/ Charlotte Sutcliffe (Corporate Broking)
Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715
David Poutney/ James Serjeant
IFC Advisory Ltd (Financial PR and Tel: 020 3934 6630
IR)
Tim Metcalfe/ Graham Herring/ Zach COG@investor-focus.co.uk
Cohen
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTSEDFWMEESESF
(END) Dow Jones Newswires
January 27, 2022 01:59 ET (06:59 GMT)
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024